Single-Use Boosts Fill/Finish in Commercial Biomanufacturing
Single-use technologies have become increasingly prevalent in final fill/finish operations for biologics.
The increasing number of biologic drugs in development is driving the need for more efficient and cost-effective manufacturing technologies, including in single-use technologies for final fill/finish. Single-use technologies have become increasingly prevalent in fill/finish as a result of industry demand.
BioPharm Internationalspoke to BJ Hull, vice-president and general manager (Camden), Emergent BioSolutions; Sara Bell, senior marketing manager, Single-use Solutions, MilliporeSigma, a business of Merck KGaA, Darmstadt, Germany; and Claus Feussner, PhD, senior vice-president Vetter Development Service, Vetter Pharma-Fertigung, on the adoption, benefits, and challenges of single-use systems in final fill/finish manufacturing.
Read this article in BioPharm International's Single-Use Systems 2018 eBook.
Article Details
BioPharm International
eBook: BioPharm International Single-Use Systems
Vol. 31
June 2018
Pages: 13–17
Citation
When referring to this article, please cite it as F. Mirasol, “Single-Use Boosts Fill/Finish in Commercial Biomanufacturing,” BioPharm International Single-Use Systems eBook (June 2018).
Thermo Fisher Opens Advanced Therapies Collaboration Center in California
April 18th 2025The 6000-square-foot facility will provide cell therapy developers the support they need to transition to CGMP manufacturing, and an expanded footprint of the new center is expected to open in Philadelphia later in 2025.
